Advances in Treatment for Retinal Disease: What Optometrists Need to Know: Addressing Treatment Burden, Adherence, and Patient Perspectives Through Communication and Collaboration (Archived)

This educational activity has expired. You will not be able to claim credit for this activity.

Activity Description and Purpose

This is Part 4 of a 4-part series of 15-minute discussions that will help optometrists who care for patients with neovascular age-related macular degeneration and diabetic macular edema better understand how to address the burden patients face, current treatment options, the need for longer-acting treatments, and best practices. This module features an interview with a patient to help clinicians put these concepts into a real-life clinical context. This module is accredited for 0.25 COPE CE credit.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:
  • Illustrate how addressing treatment burden can be incorporated into patient encounters
Course summary
Course opens: 
Course expires: 


Mohammad Rafieetary, OD, FAAO, FORS
Consultative Optometric Physician
Charles Retina Institute
Germantown, Tennessee
Adjunct Faculty
Southern College of Optometry
Memphis, Tennessee

Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Reno, Nevada


Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.


Arshad M. Khanani, MD, MA, is a consultant for Alimera Sciences, Allergan, Apellis Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch & Lomb Incorporated, Broadwing Bio, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Cholgene Therapeutics Inc,
F. Hoffmann-La Roche Ltd, 4DMT, Gemini Therapeutics, Genentech, Inc, Graybug, Inc, Gyroscope, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kato Pharmaceuticals, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Oculis, Opthea, Oxurion NV, PolyPhotonix, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Retrotope Inc*, Thea Pharmaceuticals Limited, and Unity Biotechnology; is on the speakers bureau for Allergan, Genentech, Inc, and Novartis Pharmaceuticals Corporation; is a contracted researcher for Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, 4DMT, Gemini Therapeutics, Genentech, Inc, Gyroscope, Iveric Bio, Inc, Kodiak Sciences Inc, NGM Bio, Novartis Pharmaceuticals Corporation, Oculis, Opthea, Oxurion NV, Regenxbio Inc, and Unity Biotechnology; and has stock options in Aviceda Therapeutics, PolyPhotonix, and Retrotope Inc*.

Mohammad Rafieetary, OD, is an advisory board member of Apellis Pharmaceuticals, Cardinal Health, Heidelberg Engineering GmbH, Iveric Bio, Inc, Notal Vision, Optos, and Regeneron Pharmaceuticals, Inc; and is on the speakers bureau for Heidelberg Engineering GmbH, Notal Vision, Optos, Regeneron Pharmaceuticals, Inc, and Spark Therapeutics, Inc.

* The financial relationship existed during the last 24 months but has now ended

Planners, Managers, and Writers

Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.

Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

COPE approved for 0.25 CE credit for optometrists.
COPE Course ID: 82155-TD
COPE Course Category: Treatment & Management of Ocular Disease


Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Genentech, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.

This CE activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 282.4

Please login or register to take this course.

This educational activity has expired. You will not be able to claim credit for this activity.